207 related articles for article (PubMed ID: 25758612)
1. Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy.
Weiss A; Bonvin D; Berndsen RH; Scherrer E; Wong TJ; Dyson PJ; Griffioen AW; Nowak-Sliwinska P
Sci Rep; 2015 Mar; 5():8990. PubMed ID: 25758612
[TBL] [Abstract][Full Text] [Related]
2. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
3. Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization.
Weiss A; van Beijnum JR; Bonvin D; Jichlinski P; Dyson PJ; Griffioen AW; Nowak-Sliwinska P
J Cell Mol Med; 2014 Mar; 18(3):480-91. PubMed ID: 24450440
[TBL] [Abstract][Full Text] [Related]
4. Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib.
Huang Q; Zhou C; Chen X; Dong B; Chen S; Zhang N; Liu Y; Li A; Yao M; Miao J; Li Q; Wang Z
PLoS One; 2015; 10(10):e0141395. PubMed ID: 26513662
[TBL] [Abstract][Full Text] [Related]
5. Folate-Hapten-Mediated Immunotherapy Synergizes with Vascular Endothelial Growth Factor Receptor Inhibitors in Treating Murine Models of Cancer.
Bandara NA; Bates CD; Lu Y; Hoylman EK; Low PS
Mol Cancer Ther; 2017 Mar; 16(3):461-468. PubMed ID: 27980109
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
7. Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction.
Kleibeuker EA; Ten Hooven MA; Castricum KC; Honeywell R; Griffioen AW; Verheul HM; Slotman BJ; Thijssen VL
Cancer Med; 2015 Jul; 4(7):1003-15. PubMed ID: 25828633
[TBL] [Abstract][Full Text] [Related]
8. The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature.
Fenton BM; Paoni SF
Cancer Res; 2007 Oct; 67(20):9921-8. PubMed ID: 17942924
[TBL] [Abstract][Full Text] [Related]
9. Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model.
Zhang K; Waxman DJ
Mol Cancer Ther; 2013 May; 12(5):787-98. PubMed ID: 23635653
[TBL] [Abstract][Full Text] [Related]
10. A chorioallantoic membrane model for the determination of anti-angiogenic effects of imatinib.
Özcetin A; Aigner A; Bakowsky U
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):711-5. PubMed ID: 23891770
[TBL] [Abstract][Full Text] [Related]
11. Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effect.
Kleibeuker EA; Fokas E; Allen PD; Kersemans V; Griffioen AW; Beech J; Im JH; Smart SC; Castricum KC; van den Berg J; Schulkens IA; Hill SA; Harris AL; Slotman BJ; Verheul HM; Muschel RJ; Thijssen VL
Oncotarget; 2016 Nov; 7(47):76613-76627. PubMed ID: 27780936
[TBL] [Abstract][Full Text] [Related]
12. Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model.
Denorme M; Yon L; Roux C; Gonzalez BJ; Baudin E; Anouar Y; Dubessy C
Cancer Lett; 2014 Oct; 352(2):236-44. PubMed ID: 25016061
[TBL] [Abstract][Full Text] [Related]
13. Murine colitis treated with multitargeted tyrosine kinase inhibitors.
Knod JL; Crawford K; Dusing M; Frischer JS
J Surg Res; 2016 Feb; 200(2):501-7. PubMed ID: 26521099
[TBL] [Abstract][Full Text] [Related]
14. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models.
Schueneman AJ; Himmelfarb E; Geng L; Tan J; Donnelly E; Mendel D; McMahon G; Hallahan DE
Cancer Res; 2003 Jul; 63(14):4009-16. PubMed ID: 12873999
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment.
Hatipoglu G; Hock SW; Weiss R; Fan Z; Sehm T; Ghoochani A; Buchfelder M; Savaskan NE; Eyüpoglu IY
Cancer Sci; 2015 Feb; 106(2):160-70. PubMed ID: 25458015
[TBL] [Abstract][Full Text] [Related]
16. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer.
Huynh H; Ong R; Zopf D
J Exp Clin Cancer Res; 2015 Oct; 34():132. PubMed ID: 26514182
[TBL] [Abstract][Full Text] [Related]
18. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
Chung AS; Kowanetz M; Wu X; Zhuang G; Ngu H; Finkle D; Komuves L; Peale F; Ferrara N
J Pathol; 2012 Aug; 227(4):404-16. PubMed ID: 22611017
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis, and Biological Evaluation of Axitinib Derivatives.
Wei N; Liang J; Peng S; Sun Q; Dai Q; Dong M
Molecules; 2018 Mar; 23(4):. PubMed ID: 29570686
[TBL] [Abstract][Full Text] [Related]
20. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
Wang D; Tang F; Wang S; Jiang Z; Zhang L
Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
